Zacks Investment Research | Oct 04, 2017 09:03PM ET
Henry Schein Medical, a subsidiary of Henry Schein, Inc. (NASDAQ:HSIC) , recently inked an agreement with Cerebral Assessment Systems (“CAS”) to distribute Cognivue. This is the first computerized cognitive assessment screening device cleared by the FDA for the detection of early signs of dementia. We believe this development will bolster growth for the company in the field of mental cognitive diseases.
CAS is a medical device company engaged in researching and commercializing automated solutions for the routine measurement and monitoring of brain health.
According to the company, Cognivue is a fully-automated solution displaying visual stimuli on a computer screen. Physicians conduct quantitative analysis of brain health to get a single score of overall brain functional integrity. The results are stored in the cloud enabling doctors to observe current brain health and identify potential issues that can be addressed before problems worsen.
Henry Schein is consistently working toward boosting its Medical segment. Notably, worldwide Medical revenues rose 6.1% year over year in the last reported second quarter. Recently, Henry Schein announced a partnership with Simplifeye to create a mobile platform for health care providers who use its practice management and electronic health record software — MicroMD.
According to a report by Research and Markets, the global treatment for syndromes of dementia and movement disorders market is anticipated to reach a value of $21,154.8 million in 2020, at a CAGR of 8.6%.Considering the huge potential of the market, we believe the latest development is strategic.
Over the past year, Henry Schein has underperformed the broader Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.